Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Targeted Oncology|September 1, 2023
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm AnalysisDevon J Boyne, David E Dawe, Huma Shakir, et al.JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.Research Involvement and Engagement|April 2, 2024
Acceptability of automatic referrals to supportive and palliative care by patients living with advanced lung cancer: qualitative interviews and a co-design processSadia Ahmed, Jessica Simon, Patricia Biondo, et al.JAMA Network Open|December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination ImmunotherapyAlexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.Lung Cancer (Amsterdam, Netherlands)|May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE studyPaul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.Journal of Pain and Symptom Management|February 6, 2025
Patient-Rated Acceptability of Automatic Palliative Care Referral: A Prospective Cohort StudySeema King, Aynharan Sinnarajah, Sadia Ahmed, et al.Pageof 4